News of Note—Altimmune, Ebola outbreak and more

newspaper
(Pixabay)

Here is some other vaccine news of note for the week:

> Altimmune CEO Bill Enright plans to step down from his post early next year, or when a successor is appointed. Washington Business Journal article

> Teams fighting the Ebola outbreak are struggling to find potential vaccine recipients. Stat News article

> Seqirus' Afluria Quadrivalent won a label expansion in the U.S. It's now approved for people 6 months and older. Release

Read more on

Suggested Articles

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.